soul trial oral semaglutide cardiovascular outcomes 2024 nejm 2025 Oral Semaglutide Reduces Cardiovascular Events in People with Ongoing #GLP1 -RA Trials on – SOUL Trial Shows Oral Semaglutide

What is 5-amino-1MQ

At standard doses, they are used to treat obesity and type 2 diabetes

That extended duration is what makes weekly dosing possible, but it also means the body is exposed to sustained amylin receptor activation far beyond what natural physiology produces

It also helps maintain a bright, even skin tone by regulating melanin production

ng gi sn phm cn thnCht lng sn phm ok thch Phm Ngc Trm mua ti rocy.vn c xp hng 5 5 sao Ln u mua shop nhng thy kh ng, t cch ng gi n thi t vn u rt tt

Results: Nausea, vomiting, diarrhea, and constipation were the most frequently reported GI adverse events, generally dose-dependent and transient